AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Nuvectis Pharma Inc (NASDAQ:NVCT)
9.31 USD
-0.200 2.103%Sponsored Reports
Loading...
| Previous Close (in USD) | 9.51 |
|---|---|
| Change | -0.200 2.103% |
| 52 W H/L (in USD) | 18.650/5.850 |
| EBITDA (in USD) | -- |
| PE Ratio | -- |
| Volume | 68801 |
| Diluted Eps TTM | -1.50 |
| Total Assets (in USD) | 19.185M |
|---|---|
| Total Liabilities (in USD) | 6.984M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 19.126M |
| Market Cap (in USD) | 120.783 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Nuvectis Pharma Inc
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Employees: 13
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Ron Bentsur M.B.A. | Co-Founder, Chairman, CEO & Pres | 1966 |
| 2. | Dr. Enrique Poradosu Ph.D. | Co-Founder, Exec. VP, Chief Scientific & Bus. Officer | 1967 |
| 3. | Mr. Shay Shemesh | Co-Founder, EVP, Chief Devel. & Operations Officer | 1984 |
| 4. | Mr. Michael Carson CPA | VP of Fin. | 1976 |
| 5. | Mr. Ron Bentsur M.B.A. | Co-Founder, Chairman, CEO & President | 1966 |
| 6. | Dr. Enrique Poradosu Ph.D. | Co-Founder, Executive VP, Chief Scientific & Business Officer | 1967 |
| 7. | Mr. Shay Shemesh | Co-Founder, Executive VP, Chief Development & Operations Officer | 1984 |
| 8. | Mr. Michael Carson CPA | Vice President of Finance | 1977 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.920 2.144% | 42.715 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.750 1.734% | 42.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.250 0.765% | 420.63 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.030 2.659% | 600.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 |
|---|---|---|---|
| Income Before Tax | -19.085M | -12.89M | - |
| Minority Interest | - | - | - |
| Net Income | -18.787M | -12.886M | - |
| Selling General Administrative | 6.007M | 3.349M | - |
| Gross Profit | -19.085M | -12.894M | - |
| Reconciled Depreciation | - | - | - |
| Ebit | -19.234M | -12.894M | -0.024M |
| Ebitda | -19.234M | -12.894M | - |
| Depreciation And Amortization | 0.298M | 0.004M | - |
| Operating Income | -19.234M | -12.894M | - |
| Other Operating Expenses | 19.234M | 12.894M | - |
| Interest Expense | 0.149M | 0.004M | 0M |
| Tax Provision | - | - | - |
| Interest Income | 0.149M | 0.004M | - |
| Net Interest Income | 0.149M | 0.004M | - |
| Income Tax Expense | -0.298M | -0.004M | - |
| Total Revenue | 0.149M | 0M | - |
| Total Operating Expenses | 19.234M | 12.894M | - |
| Cost Of Revenue | 19.234M | 12.894M | - |
| Total Other Income Expense Net | 0.149M | 0.004M | - |
| Net Income From Continuing Ops | -19.234M | -12.89M | - |
| Net Income Applicable To Common Shares | -19.085M | -12.89M | -0.024M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 |
|---|---|---|---|---|
| Total Assets | 19.185M | 20.405M | 6.657M | 6.657M |
| Intangible Assets | - | - | - | - |
| Other Current Assets | 0.059M | 0.412M | 0.091M | 0.091M |
| Total Liab | 6.984M | 6.186M | 17.665M | 0.01M |
| Total Stockholder Equity | 12.201M | 14.219M | -11.008M | -0.01M |
| Other Current Liab | 4.213M | 3.276M | 1.361M | - |
| Common Stock | 17768.824M | 14752.403M | - | - |
| Capital Stock | 0M | 0M | 0M | 0M |
| Retained Earnings | -54.245M | -31.985M | -12.9M | -0.01M |
| Good Will | - | - | - | - |
| Other Assets | - | - | 0.824M | - |
| Cash | 19.126M | 19.993M | 5.742M | 5.742M |
| Cash And Equivalents | - | - | - | - |
| Total Current Liabilities | 6.984M | 6.186M | 2.419M | 0.01M |
| Current Deferred Revenue | - | - | - | - |
| Net Debt | -19.126M | -19.993M | -5.742M | - |
| Short Term Debt | - | - | - | - |
| Short Long Term Debt | - | - | - | - |
| Short Long Term Debt Total | - | - | - | - |
| Other Stockholder Equity | -17702.378M | 25.799M | -13.354M | - |
| Property Plant Equipment | - | - | - | - |
| Total Current Assets | 19.185M | 20.405M | 5.833M | 5.833M |
| Long Term Investments | - | - | - | - |
| Short Term Investments | - | - | - | - |
| Net Receivables | - | - | - | - |
| Long Term Debt | - | - | - | - |
| Inventory | - | - | - | - |
| Accounts Payable | 2.771M | 2.91M | 1.058M | 0.01M |
| Accumulated Other Comprehensive Income | - | -14752.403M | - | - |
| Non Currrent Assets Other | - | - | 0.824M | - |
| Non Current Assets Total | 0M | 0M | 0.824M | 0.824M |
| Capital Lease Obligations | - | - | - | - |
| Long Term Debt Total | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 |
|---|---|---|---|
| Investments | 0M | 0M | - |
| Total Cashflows From Investing Activities | - | - | - |
| Total Cash From Financing Activities | 27.81M | 15.246M | 15.246M |
| Net Income | -19.085M | -12.89M | -0.024M |
| Change In Cash | 14.251M | 5.742M | 5.742M |
| Begin Period Cash Flow | 5.742M | 0M | - |
| End Period Cash Flow | 19.993M | 5.742M | - |
| Total Cash From Operating Activities | -13.559M | -9.504M | -9.504M |
| Depreciation | - | - | - |
| Other Cashflows From Investing Activities | - | - | - |
| Dividends Paid | - | - | - |
| Change To Inventory | - | - | - |
| Sale Purchase Of Stock | 27.81M | - | - |
| Other Cashflows From Financing Activities | -4.069M | 15.246M | -4.069M |
| Capital Expenditures | 0M | 0M | 0M |
| Change In Working Capital | 3.819M | 1.494M | - |
| Other Non Cash Items | - | - | - |
| Free Cash Flow | -13.559M | -9.504M | - |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 181040 |
| 2. | iShares Russell 2000 ETF | 2 years ago | 159610 |
| 3. | Fidelity Small Cap Index | 2 years ago | 77570 |
| 4. | iShares Russell 2000 Growth ETF | 2 years ago | 63187 |
| 5. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 57030 |
| 6. | State St Russell Sm/Mid Cp® Indx NL Cl C | 2 years ago | 56400 |
| 7. | Vanguard Russell 2000 ETF | 2 years ago | 28120 |
| 8. | Fidelity Extended Market Index | 2 years ago | 25483 |
| 9. | State St Russell Sm Cap® Indx SL Cl I | 2 years ago | 21500 |
| 10. | NT R2000 Growth Index Fund - NL | 2 years ago | 20570 |
| 11. | NT R2000 Index Fund - NL | 2 years ago | 19744 |
| 12. | Schwab Small Cap Index | 2 years ago | 17590 |
| 13. | NT R2000 Index Fund - DC - NL - 2 | 2 years ago | 15680 |
| 14. | iShares Micro-Cap ETF | 2 years ago | 15333 |
| 15. | NT R2000 Growth Index Fund - L | 2 years ago | 15048 |
| 16. | Northern Trust Russell 2000 Growth Index | 2 years ago | 15048 |
| 17. | iShares Russell 2000 Small-Cap Idx Instl | 2 years ago | 14205 |
| 18. | Russell 2000 Index Non-Lendable Fund E | 2 years ago | 13120 |
| 19. | BlackRock Extended Mkt Composite | 2 years ago | 12428 |
| 20. | Russell 3000 Screened Index Composite | 2 years ago | 12100 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Barclays PLC | 2 years ago | 10254 |
| 2. | BlackRock Inc | 2 years ago | 387891 |
| 3. | Vanguard Group Inc | 2 years ago | 294283 |
| 4. | Baldwin Brothers Inc | 2 years ago | 142040 |
| 5. | Geode Capital Management, LLC | 2 years ago | 131657 |
| 6. | State Street Corporation | 2 years ago | 118279 |
| 7. | Northern Trust Corp | 2 years ago | 61574 |
| 8. | Renaissance Technologies Corp | 2 years ago | 51800 |
| 9. | Millennium Management LLC | 2 years ago | 34011 |
| 10. | Forbes J M & Co | 2 years ago | 34000 |
| 11. | GSA Capital Partners LLP | 2 years ago | 27313 |
| 12. | Susquehanna International Group, LLP | 2 years ago | 25670 |
| 13. | Marshall Wace Asset Management Ltd | 2 years ago | 24813 |
| 14. | Morgan Stanley - Brokerage Accounts | 2 years ago | 22915 |
| 15. | Two Sigma Investments LLC | 2 years ago | 22771 |
| 16. | Charles Schwab Investment Management Inc | 2 years ago | 19920 |
| 17. | Edmond de Rothschild Holding S.A. | 2 years ago | 19170 |
| 18. | Bank of New York Mellon Corp | 2 years ago | 19150 |
| 19. | Nuveen Asset Management, LLC | 2 years ago | 11883 |
| 20. | UBS Group AG | 2 years ago | 8060 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...